Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: EML2

Gene summary for EML2

Gene summary.

Gene information	Species	Human
	Gene symbol	EML2
	Gene ID	24139
	Gene name	EMAP like 2
	Gene Alias	ELP70
	Cytomap	19q13.32
	Gene Type	protein-coding
	GO ID	GO:0000226
	UniProtAcc	O95834

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
24139	EML2	HTA11_347_2000001011	Human	Colorectum	AD	6.68e-09	4.34e-01	-0.1954
24139	EML2	HTA11_83_2000001011	Human	Colorectum	SER	1.22e-06	4.74e-01	-0.1526
24139	EML2	HTA11_696_2000001011	Human	Colorectum	AD	2.67e-09	4.81e-01	-0.1464
24139	EML2	HTA11_1391_2000001011	Human	Colorectum	AD	6.49e-09	5.85e-01	-0.059
24139	EML2	HTA11_7696_3000711011	Human	Colorectum	AD	3.82e-14	5.36e-01	0.0674
24139	EML2	A015-C-203	Human	Colorectum	FAP	1.34e-08	-1.56e-01	-0.1294
24139	EML2	A001-C-108	Human	Colorectum	FAP	3.00e-03	-1.36e-01	-0.0272
24139	EML2	A002-C-205	Human	Colorectum	FAP	2.35e-04	-1.98e-01	-0.1236
24139	EML2	A015-C-104	Human	Colorectum	FAP	1.60e-11	-2.41e-01	-0.1899
24139	EML2	A001-C-014	Human	Colorectum	FAP	4.77e-03	-1.04e-01	0.0135
24139	EML2	A002-C-016	Human	Colorectum	FAP	1.51e-06	-1.75e-01	0.0521
24139	EML2	A015-C-002	Human	Colorectum	FAP	3.72e-02	-2.34e-01	-0.0763
24139	EML2	A001-C-203	Human	Colorectum	FAP	2.70e-02	-1.73e-01	-0.0481
24139	EML2	A002-C-116	Human	Colorectum	FAP	1.02e-08	-2.21e-01	-0.0452
24139	EML2	A018-E-020	Human	Colorectum	FAP	1.94e-03	-1.80e-01	-0.2034
24139	EML2	F034	Human	Colorectum	FAP	2.60e-05	-1.42e-01	-0.0665
24139	EML2	F072B	Human	Colorectum	FAP	7.06e-03	-1.81e-01	0.257
24139	EML2	CRC-3-11773	Human	Colorectum	CRC	3.63e-02	-1.57e-01	0.2564
24139	EML2	LZE2T	Human	Esophagus	ESCC	3.85e-03	2.37e-01	0.082
24139	EML2	LZE4T	Human	Esophagus	ESCC	1.12e-14	4.90e-01	0.0811

Page: 1 2 3 4 5 6 7

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:1902903	Colorectum	AD	regulation of supramolecular fiber organization	139/3918	383/18723	2.01e-12	3.19e-10	139
GO:0032271	Colorectum	AD	regulation of protein polymerization	94/3918	233/18723	1.01e-11	1.29e-09	94
GO:0051258	Colorectum	AD	protein polymerization	112/3918	297/18723	1.85e-11	2.27e-09	112
GO:0043254	Colorectum	AD	regulation of protein-containing complex assembly	148/3918	428/18723	2.64e-11	3.18e-09	148
GO:0010639	Colorectum	AD	negative regulation of organelle organization	114/3918	348/18723	1.41e-07	6.49e-06	114
GO:0032272	Colorectum	AD	negative regulation of protein polymerization	36/3918	80/18723	1.13e-06	3.72e-05	36
GO:1902904	Colorectum	AD	negative regulation of supramolecular fiber organization	60/3918	167/18723	5.23e-06	1.35e-04	60
GO:0031333	Colorectum	AD	negative regulation of protein-containing complex assembly	52/3918	141/18723	9.27e-06	2.18e-04	52
GO:0051494	Colorectum	AD	negative regulation of cytoskeleton organization	58/3918	163/18723	1.04e-05	2.40e-04	58
GO:0070507	Colorectum	AD	regulation of microtubule cytoskeleton organization	44/3918	148/18723	7.05e-03	4.31e-02	44
GO:19029031	Colorectum	SER	regulation of supramolecular fiber organization	114/2897	383/18723	7.32e-13	1.95e-10	114
GO:00322711	Colorectum	SER	regulation of protein polymerization	78/2897	233/18723	5.71e-12	1.17e-09	78
GO:00512581	Colorectum	SER	protein polymerization	91/2897	297/18723	2.72e-11	5.06e-09	91
GO:00432541	Colorectum	SER	regulation of protein-containing complex assembly	119/2897	428/18723	3.34e-11	5.86e-09	119
GO:00106391	Colorectum	SER	negative regulation of organelle organization	90/2897	348/18723	3.14e-07	1.69e-05	90
GO:00322721	Colorectum	SER	negative regulation of protein polymerization	31/2897	80/18723	3.67e-07	1.96e-05	31
GO:19029041	Colorectum	SER	negative regulation of supramolecular fiber organization	50/2897	167/18723	1.63e-06	7.23e-05	50
GO:00514941	Colorectum	SER	negative regulation of cytoskeleton organization	48/2897	163/18723	4.34e-06	1.63e-04	48
GO:00313331	Colorectum	SER	negative regulation of protein-containing complex assembly	43/2897	141/18723	5.03e-06	1.86e-04	43
GO:00432544	Colorectum	FAP	regulation of protein-containing complex assembly	101/2622	428/18723	5.18e-08	4.07e-06	101

Page: 1 2 3 4 5 6 7 8

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

EML2

SNV

Missense_Mutation

c.1546N>A

p.Asp516Asn

p.D516N

O95834

protein_coding

deleterious(0.01)

probably_damaging(0.995)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

EML2

SNV

Missense_Mutation

rs774032487

c.808N>T

p.Arg270Trp

p.R270W

O95834

protein_coding

deleterious(0)

probably_damaging(0.95)

TCGA-AC-A3W6-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Unknown

EML2

SNV

Missense_Mutation

novel

c.940A>T

p.Ile314Phe

p.I314F

O95834

protein_coding

deleterious(0)

benign(0.033)

TCGA-BH-A0BJ-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

EML2

SNV

Missense_Mutation

c.2326N>C

p.Asp776His

p.D776H

O95834

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-BH-A0HP-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Chemotherapy

doxorubicin

EML2

SNV

Missense_Mutation

c.1421N>T

p.Gly474Val

p.G474V

O95834

protein_coding

deleterious(0)

probably_damaging(0.944)

TCGA-E2-A159-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cyclophosphamide

EML2

insertion

Nonsense_Mutation

novel

c.1889_1890insGCACGAATGAAGCAAACACATATTCCC

p.Ser630delinsArgHisGluTerSerLysHisIlePhePro

p.S630delinsRHE*SKHIFP

O95834

protein_coding

TCGA-AN-A04D-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

EML2

SNV

Missense_Mutation

c.2380N>T

p.Asp794Tyr

p.D794Y

O95834

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-DS-A0VK-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

carboplatin

EML2

SNV

Missense_Mutation

c.1021N>T

p.Arg341Cys

p.R341C

O95834

protein_coding

deleterious(0)

probably_damaging(0.997)

TCGA-AA-3715-01

Colorectum

colon adenocarcinoma

Male

>=65

I/II

Unknown

EML2

SNV

Missense_Mutation

c.1022N>A

p.Arg341His

p.R341H

O95834

protein_coding

tolerated(0.17)

probably_damaging(0.996)

TCGA-AA-3986-01

Colorectum

colon adenocarcinoma

Male

>=65

I/II

Unknown

EML2

SNV

Missense_Mutation

c.856G>A

p.Ala286Thr

p.A286T

O95834

protein_coding

deleterious(0)

probably_damaging(0.995)

TCGA-AD-6895-01

Colorectum

colon adenocarcinoma

Male

>=65

III/IV

Unknown

Page: 1 2 3 4 5 6 7 8

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1